Fully leveraging the global research and development platform, we have been exploring pipeline opportunities for more than 20 innovative mAb candidates, with significant potential for a variety of PD-1-based immuno-oncology combination therapies, focusing on the therapeutic areas of oncology, autoimmune diseases and ophthalmic diseases. We keep the momentum for a diversified innovation by enhancing internal innovation capacities and reaching out to more strategic partners. The global innovation center is responsible for late-stage development and early-stage development to ensure the highly productive and cost-efficient R&D processes.
We have established a quality management system that covers the entire product lifecycle in accordance with the quality standards of the US, the EU and China. Xuhui Facility, constructed in 2016 with commercial capacity of 24,000L,and its supporting quality management system are certificated by China GMP, the EU GMP, participating members of PIC/S Indonesia’s BPOM GMP and Brazil’s ANVISA GMP. Songjiang First Plant, constructed in 2020 with commercial capacity of 24,000L, is also certificated by China GMP and the EU GMP along with the quality management system. Meanwhile, the construction of Songjiang Second Plant Phase 1 Project is on track. The first and second stages aim to achieve a total capacity of 36,000L. The third stage aims to reach 60,000L capacity.
While ramping up capacity progress and cementing quality management, Henlius strikes a pioneer path of adopting cutting-edge technology, such as continuous manufacturing technology, to bring down cost and streamline production process.
We have built an in-house commercial team focused on domestic market. The team is responsible for the commercialisation of our core oncology products including HANQUYOU (trastuzumab), HANBEITAI (bevacizumab injection), HANSIZHUANG (serplulimab) etc. We have built an in-house commercial team focused on domestic market, covering marketing, access, channel, pricing, strategy and sales and compromising of about 1500 professionals; we have also joined forces with global partners, expanding our reach in major markets as well as emerging markets worldwide.